Although the mechanisms of action for the inadequate response are still unclear, other SUA-lowering drugs may be somewhat better in terms of efficacy for patients with a dysfunctional ABCG2 allele, which puts them at higher risk of developing hyperuricemia/gout. This evidence concerns the gene ABCG2 and hyperuricemia.